Impact of HemoDiaFIltration on Physical Activity and Self- Reported Outcomes

Chronic Kidney Disease Clinical Trial

— HDFIT  

Official title:

Impact of HemoDiaFIltration on Physical Activity and Self-reported Outcomes: a Randomized Controlled Trial (HD-FIT Trial)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02787161
• Other study ID #: PUCPR02
• Status: Completed
• Phase: N/A
• Start date: August 2016
• Est. completion date: September 2018

Study information

• Verified date: September 2019
• Source: Pontifícia Universidade Católica do Paraná
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized controlled clinical trial that will analyze the impact of high volume online HDF in comparison to high-flux HD on measured physical activity.

Description:

HD-FIT is a randomized controlled clinical trial that will analyze the impact of high volume online HDF in comparison to high-flux HD on measured physical activity (number of steps measured in the dialysis day) as a primary endpoint. The analysis of additional accelerometer data, HRQOL and time to recover from a dialysis session will be used as other outcomes. The study will also capture safety data, based on intradialytic events, hospitalization and mortality. Biochemical (according to the local requirements) and drug prescription data will be monitored for pharma-economic analysis. Serum samples will be collected for future analysis of additional biomarkers.

In summary, patients will go through a 4 week run in period on high flux HD. After this, patients will be randomized to the intervention of high volume online HDF for 6 months, or will continue on high flux HD; both groups will be observed for a 12 month follow up period. Patients will be evaluated for physical activity, HRQOL, laboratories and other measures at the baseline, 3 month, and 6 month time points. Evaluation will be repeated in 3 and 6-months. HRQOL, laboratories, and other outcomes will be tracked over the post-interventional follow up period that lasts 12 months after randomization.

Data will be analyzed according to an intention-to-treat principle (i.e., according to assigned instead of received treatment). With an enrollment target of 110 participants in each arm (considering a drop out of 20%) we estimate the 86 patients will complete the follow up in each arm, what will provide the trial a 90% power to detect a 20% effect with respect to the primary outcome (predefined as a 20% increase in average total steps at the dialysis day in the HDF group compared to the HD group). Because of the nature of the intervention, it will not possible to blind the patients, the local study nurses, or the investigators for the treatment assignment.

Fourteen dialysis centers will be invited to participate. Each participating center will receive two 5008S machines and Cordiax dialyzers to be used in the study of 10 patients in each center. Additional patients can be randomized per center with approval of the steering committee. Centralized randomization will based on a 1:1 protocol, stratified by participating center.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 195
• Est. completion date: September 2018
• Est. primary completion date: April 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients treated three times per week with HD for at least 3 months and up to 24 months;

• Clinically stable according to the evaluation of the investigator;

• Kt/V of > 1.2;

• Patients with an arteriovenous fistula/graft and permanent catheters with adequate flow.

Exclusion Criteria:

• Age below 18 years;

• Life expectancy less than 3 months because of nonrenal disease;

• Participation in another clinical intervention trial;

• Severe non-compliance regarding frequency and duration of dialysis treatment;

• Patients with severe limitation to mobility (amputated, neurologic and muscular disorders) will be excluded from the study.

Related Conditions & MeSH terms

• Chronic Kidney Disease
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Device:
• Hemodiafiltration
High volume online HDF
• Hemodialysis
High-flux HD

Locations

Country	Name	City	State
Brazil	Instituto Médico Nefrológico	Belo Horizonte	Minas Gerais
Brazil	Nefron Contagem	Contagem	Minas Gerais
Brazil	Irmandade da Santa Casa de Misericórdia de Curitiba	Curitiba	Paraná
Brazil	Fundação Pro Rim	Joinville	Santa Catarina
Brazil	Hospital de Clínicas de Porto Alegre	Porto Alegre	Rio Grande Do Sul
Brazil	Hospital São Lucas PUCRS	Porto Alegre	Rio Grande Do Sul
Brazil	Clínica de Diálise Ingá	Rio de Janeiro
Brazil	Clínica de Doenças Renais - São Lourenço	Rio de Janeiro
Brazil	Clínica de Doenças Renais - Un. Botafogo	Rio de Janeiro
Brazil	CETENE	São Paulo
Brazil	Hospital Alemão Oswaldo Cruz	São Paulo
Brazil	Hospital do Rim e Universidade Federal de São Paulo	São Paulo
Brazil	Instituto de Nefrologia de Taubaté	Taubaté	São Paulo

Sponsors (2)

Lead Sponsor	Collaborator
Pontifícia Universidade Católica do Paraná	Fresenius AG

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The difference in the change in step counts per 24 hours on dialysis days from baseline to the 6-month follow up in patients treated with high volume online HDF versus high-flux HD	To capture activity in the study, we will use the Actigraph ™ device to measure acceleration and count steps during 7 days at baseline, 3 and 6 months evaluations, according to a previously described protocol for dialysis patients. A 4s step filter is an intrinsic property of the Actigraph ™ that screens out erroneous steps that might result as from shuffling, standing up, sitting up, sitting down, and vibrations from a moving vehicle. The Actigraph ™ is lightweight (19g), clips at the waist, and provides feedback with on-instrument digital display of step counts. It interfaces with the internet via bluetooth, allowing upload of date and time stamped step counts.	Baseline, 3 months and 6 months
Primary	The difference in the change in minutes of moderate-to-vigorous physical activity (MVPA) per 24 hours on dialysis days from baseline to the 6-month follow up in patients treated with high volume online HDF versus high-flux HD		Baseline, 3 months and 6 months
Secondary	The difference in the change in self-reported dialysis recovery time from baseline to the 6-month follow up in patients treated with high volume online HDF versus high-flux HD	Dialysis recovery time will be assessed at baseline and at 3 and 6 months of follow-up in both arms. The dialysis recovery time survey asks the question, " How long does it take to recover from a dialysis session?" . This test has been validated in HD studies, and it is interpreted easily, is easy to respond to, shows stability over time by test-retest, shows both convergent and divergent validity, and is sensitive to change.	Baseline, 3 months and 6 months
Secondary	The difference in the change in SF-36 scores from baseline to the 6-month follow up in patients treated with high volume online HDF versus high-flux HD	HRQOL will be assessed at baseline and at 3 and 6 months of follow- up with the Kidney Disease Quality of Life - Short Form (KDQOL-SF), adapted and validated to Brazilian Portuguese. This questionnaire covers different domains to face the multidimensional nature of HRQOL. The eight domains of the SF-36 can be summarized in two summary scores, one for physical functioning (the physical composite score [ PCS]) and one for mental functioning (the mental composite score [MCS]). Questionnaires will be applied at the baseline, and 3 and 6 months in both arms. Analysis will include PCS and MCS.	Baseline, 3 months and 6 months
Secondary	Pharmacoeconomy (drug use, hospitalization)	Income, social status, prescription of drugs, hospitalization	Baseline, 3 months and 6 months
Secondary	Intradialytic events	Events	Baseline, 3 months and 6 months
Secondary	Mortality	Survival	Baseline, 3 months and 6 months